[go: up one dir, main page]

GB0325830D0 - Organic compounds - Google Patents

Organic compounds

Info

Publication number
GB0325830D0
GB0325830D0 GBGB0325830.8A GB0325830A GB0325830D0 GB 0325830 D0 GB0325830 D0 GB 0325830D0 GB 0325830 A GB0325830 A GB 0325830A GB 0325830 D0 GB0325830 D0 GB 0325830D0
Authority
GB
United Kingdom
Prior art keywords
organic compounds
compounds
organic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0325830.8A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to GBGB0325830.8A priority Critical patent/GB0325830D0/en
Publication of GB0325830D0 publication Critical patent/GB0325830D0/en
Priority to RU2006119504/04A priority patent/RU2006119504A/en
Priority to AU2004291276A priority patent/AU2004291276B2/en
Priority to CA002544751A priority patent/CA2544751A1/en
Priority to TW093133702A priority patent/TW200530203A/en
Priority to MXPA06005032A priority patent/MXPA06005032A/en
Priority to BRPI0416276-5A priority patent/BRPI0416276A/en
Priority to KR1020067008740A priority patent/KR20060110289A/en
Priority to EP04797621A priority patent/EP1682521A1/en
Priority to CNA2004800394258A priority patent/CN1902182A/en
Priority to JP2006538745A priority patent/JP4628366B2/en
Priority to PCT/EP2004/012497 priority patent/WO2005049585A1/en
Priority to US10/577,260 priority patent/US7612055B2/en
Priority to ARP040104052A priority patent/AR046321A1/en
Priority to PE2004001073A priority patent/PE20051006A1/en
Priority to US12/566,928 priority patent/US20100022500A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
    • C07D245/02—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
    • C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB0325830.8A 2003-11-05 2003-11-05 Organic compounds Ceased GB0325830D0 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
GBGB0325830.8A GB0325830D0 (en) 2003-11-05 2003-11-05 Organic compounds
PE2004001073A PE20051006A1 (en) 2003-11-05 2004-11-04 MACROCYCLIC LACTAM COMPOUNDS AS INHIBITORS OF ASPARTIC PROTEASES
BRPI0416276-5A BRPI0416276A (en) 2003-11-05 2004-11-04 macrocyclic lactames and pharmaceutical use thereof
EP04797621A EP1682521A1 (en) 2003-11-05 2004-11-04 Macrocyclic lactams and pharmaceutical use thereof
CA002544751A CA2544751A1 (en) 2003-11-05 2004-11-04 Macrocyclic lactams and pharmaceutical use thereof
TW093133702A TW200530203A (en) 2003-11-05 2004-11-04 Macrocyclic lactams and pharmaceutical use thereof
MXPA06005032A MXPA06005032A (en) 2003-11-05 2004-11-04 Macrocyclic lactams and pharmaceutical use thereof.
RU2006119504/04A RU2006119504A (en) 2003-11-05 2004-11-04 MACROCYCLIC LACTAMS AND THEIR PHARMACEUTICAL APPLICATIONS
KR1020067008740A KR20060110289A (en) 2003-11-05 2004-11-04 Macrocyclic Lactam and Its Pharmaceutical Uses
AU2004291276A AU2004291276B2 (en) 2003-11-05 2004-11-04 Macrocyclic lactams and pharmaceutical use thereof
CNA2004800394258A CN1902182A (en) 2003-11-05 2004-11-04 Macrocyclic lactams and pharmaceutical use thereof
JP2006538745A JP4628366B2 (en) 2003-11-05 2004-11-04 Macrocyclic lactams and their pharmaceutical use
PCT/EP2004/012497 WO2005049585A1 (en) 2003-11-05 2004-11-04 Macrocyclic lactams and pharmaceutical use thereof
US10/577,260 US7612055B2 (en) 2003-11-05 2004-11-04 Macrocyclic lactams and pharmaceutical use thereof
ARP040104052A AR046321A1 (en) 2003-11-05 2004-11-04 COMPOUNDS OF MACROCICLIC LACTORS, PREPARATION PROCEDURES AND PHARMACEUTICAL COMPOSITIONS.
US12/566,928 US20100022500A1 (en) 2003-11-05 2009-09-25 Macrocyclic Lactams and Pharmaceutical Use Thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0325830.8A GB0325830D0 (en) 2003-11-05 2003-11-05 Organic compounds

Publications (1)

Publication Number Publication Date
GB0325830D0 true GB0325830D0 (en) 2003-12-10

Family

ID=29725994

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0325830.8A Ceased GB0325830D0 (en) 2003-11-05 2003-11-05 Organic compounds

Country Status (15)

Country Link
US (2) US7612055B2 (en)
EP (1) EP1682521A1 (en)
JP (1) JP4628366B2 (en)
KR (1) KR20060110289A (en)
CN (1) CN1902182A (en)
AR (1) AR046321A1 (en)
AU (1) AU2004291276B2 (en)
BR (1) BRPI0416276A (en)
CA (1) CA2544751A1 (en)
GB (1) GB0325830D0 (en)
MX (1) MXPA06005032A (en)
PE (1) PE20051006A1 (en)
RU (1) RU2006119504A (en)
TW (1) TW200530203A (en)
WO (1) WO2005049585A1 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115747B2 (en) * 2002-06-20 2006-10-03 Pharmacia & Upjohn Company Process for preparing oxazole intermediates
GB0325830D0 (en) * 2003-11-05 2003-12-10 Novartis Ag Organic compounds
US8436006B2 (en) 2004-08-06 2013-05-07 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US8426429B2 (en) 2004-08-06 2013-04-23 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US8383637B2 (en) 2004-08-06 2013-02-26 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
GB0500683D0 (en) * 2005-01-13 2005-02-23 Novartis Ag Organic compounds
EP1851208A1 (en) * 2005-01-13 2007-11-07 Novartis AG Macrocyclic compounds useful as bace inhibitors
WO2007021793A1 (en) 2005-08-12 2007-02-22 Bristol-Myers Squibb Company Macrocyclic diaminopropanes as beta-secretase inhibitors
US8541362B2 (en) 2005-08-19 2013-09-24 Emisphere Technologies, Inc. Cyclopropyl compounds and compositions for delivering active agents
DE602006020773D1 (en) 2005-10-25 2011-04-28 Janssen Pharmaceutica Nv 2-AMINO-3,4-DIHYDROPYRIDOE3,4-DUPRYIDIDE DERIVATIVES SUITED AS INHIBITORS OF BETA-SEKRETASE (BACE)
GB0526614D0 (en) * 2005-12-30 2006-02-08 Novartis Ag Organic compounds
US7776882B2 (en) 2006-02-06 2010-08-17 Baxter Ellen W 2-amino-3,4-dihydro-quinoline derivatives useful as inhibitors of β-secretase (BACE)
US7932261B2 (en) 2006-02-06 2011-04-26 Janssen Pharmaceutica Nv Macrocycle derivatives useful as inhibitors of β-secretase (BACE)
US7868022B2 (en) 2006-02-06 2011-01-11 Janssen Pharmaceutica Nv 2-amino-quinoline derivatives useful as inhibitors of β-secretase (BACE)
MX2009000768A (en) * 2006-07-20 2009-01-28 Novartis Ag Macrocyclic lactams.
BRPI0715440A2 (en) * 2006-07-20 2013-07-23 Novartis Ag macrocyclic compounds useful as bace inhibitors
US7678784B2 (en) 2006-11-20 2010-03-16 Bristol-Myers Squibb Company Oxime-containing macrocyclic acyl guanidines as β-secretase inhibitors
US7772221B2 (en) 2007-02-09 2010-08-10 Bristol-Meyers Squibb Company Diaminopropane derived macrocycles as inhibitors of β amyloid production
US8466199B2 (en) * 2007-03-21 2013-06-18 Emisphere Technologies, Inc. Allyloxy and alkyloxy benzoic acid delivery agents
US7732434B2 (en) 2007-04-20 2010-06-08 Bristol-Myers Squibb Company Macrocyclic acyl guanidines as beta-secretase inhibitors
WO2008135488A1 (en) * 2007-05-04 2008-11-13 Medivir Ab Aspartyl protease inhibitors
KR20100107045A (en) 2008-01-28 2010-10-04 얀센 파마슈티카 엔.브이. 6-SUBSTITUTED-THIO-2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE)
CA2714008A1 (en) 2008-01-29 2009-08-06 Janssen Pharmaceutica N.V. 2-amino quinoline derivatives useful as inhibitors of .beta.-secretase (bace)
WO2010058577A1 (en) * 2008-11-20 2010-05-27 株式会社カネカ Method for producing unsaturated aminocarboxylic acid derivative
CN103370331B (en) 2011-02-08 2017-02-15 默克专利股份有限公司 Amino statin derivatives for the treatment of arthrosis
AU2012230503B2 (en) 2011-03-18 2016-07-07 Bayer Intellectual Property Gmbh N-(3-carbamoylphenyl)-1H-pyrazole-5-carboxamide derivatives and the use thereof for controlling animal pests
WO2014015934A1 (en) 2012-07-24 2014-01-30 Merck Patent Gmbh Hydroxystatin derivatives for treatment of arthrosis
CA2902080A1 (en) 2013-02-25 2014-08-28 Merck Patent Gmbh 2-amino-3,4-dihydroquinazoline derivatives and the use thereof as cathepsin d inhibitors
ES2759060T3 (en) 2013-08-06 2020-05-07 Merck Patent Gmbh Intraarticular administration of pepstatin for osteoarthritis
US11834515B2 (en) 2017-10-11 2023-12-05 Cornell University Macrocyclic compounds as proteasome inhibitors
JP7444170B2 (en) * 2019-09-02 2024-03-06 株式会社レゾナック Ionic compound, organic electronic material, organic layer, organic electronic device, organic electroluminescent device, display device, lighting device, and method for producing an organic electronic device
CN116199702B (en) * 2021-12-01 2026-01-09 上海交通大学医学院附属仁济医院 A macrocyclic lactam compound, its preparation method and application
CN116082181B (en) * 2022-12-12 2025-03-04 爱斯特（成都）生物制药股份有限公司 A method for preparing 3-amino-5-ethoxy-benzoic acid

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0535192B1 (en) 1991-04-17 1996-06-19 F. Hoffmann-La Roche Ag Novel dna gyrase inhibitors, process for their manufacture and pharmaceutical preparations containing same
TW343965B (en) 1994-03-30 1998-11-01 Hoffmann La Roche Novel mono- and bicyclic DNA gyrase inhibitors
EP1395257A1 (en) * 2001-06-12 2004-03-10 Elan Pharmaceuticals, Inc. Macrocycles useful in the treatment of alzheimer's disease
BR0210392A (en) * 2001-06-12 2004-10-13 Elan Pharm Inc Compound, methods of treating a patient who has or prevent a patient from contracting a disease or condition and preparing a compound, and, using a compound
GB0325830D0 (en) * 2003-11-05 2003-12-10 Novartis Ag Organic compounds
EP1851208A1 (en) * 2005-01-13 2007-11-07 Novartis AG Macrocyclic compounds useful as bace inhibitors
GB0500683D0 (en) * 2005-01-13 2005-02-23 Novartis Ag Organic compounds
GB0526614D0 (en) * 2005-12-30 2006-02-08 Novartis Ag Organic compounds
MX2009000768A (en) * 2006-07-20 2009-01-28 Novartis Ag Macrocyclic lactams.
BRPI0715440A2 (en) * 2006-07-20 2013-07-23 Novartis Ag macrocyclic compounds useful as bace inhibitors

Also Published As

Publication number Publication date
BRPI0416276A (en) 2007-01-23
US20070072792A1 (en) 2007-03-29
KR20060110289A (en) 2006-10-24
JP2007510002A (en) 2007-04-19
CN1902182A (en) 2007-01-24
AU2004291276A1 (en) 2005-06-02
MXPA06005032A (en) 2006-07-06
US7612055B2 (en) 2009-11-03
WO2005049585A1 (en) 2005-06-02
AR046321A1 (en) 2005-11-30
EP1682521A1 (en) 2006-07-26
US20100022500A1 (en) 2010-01-28
CA2544751A1 (en) 2005-06-02
PE20051006A1 (en) 2005-12-28
AU2004291276B2 (en) 2009-03-12
RU2006119504A (en) 2007-12-27
JP4628366B2 (en) 2011-02-09
TW200530203A (en) 2005-09-16

Similar Documents

Publication Publication Date Title
GB0325830D0 (en) Organic compounds
GB0301259D0 (en) Organic compounds
GB0303503D0 (en) Organic compounds
GB0325603D0 (en) Organic compounds
GB0306715D0 (en) Organic compounds
GB0302876D0 (en) Organic compounds
GB0300095D0 (en) Organic compounds
GB0302748D0 (en) Organic compounds
GB0301471D0 (en) Organic compounds
GB0301938D0 (en) Organic compounds
GB0303506D0 (en) Organic compounds
GB0306070D0 (en) Organic compounds
GB0306071D0 (en) Organic compounds
GB0320637D0 (en) Organic compounds
GB0302991D0 (en) Organic compounds
GB0307277D0 (en) Organic compounds
GB0307440D0 (en) Organic compounds
GB0310868D0 (en) Organic compounds
GB0308512D0 (en) Organic compounds
GB0329852D0 (en) Organic compounds
GB0320311D0 (en) Organic compounds
GB0318100D0 (en) Organic compounds
GB0315090D0 (en) Organic compounds
GB0323089D0 (en) Organic compounds
GB0302433D0 (en) Organic compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)